Terug
43
Ook genoteerd als
CLPBF
OTC
Dagbereik
€ 6,65
€ 6,73
52-Weeksbereik
€ 6,54
€ 11,44
Volume
29.067
50D / 200D Gem.
€ 7,87
/
€ 8,90
Vorige Slotkoers
€ 6,60
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 4,4 | 0,3 |
| P/B | 0,9 | 2,9 |
| ROE % | 20,1 | 3,7 |
| Net Margin % | 13,1 | 3,8 |
| Rev Growth 5Y % | 7,8 | 10,0 |
| D/E | 1,4 | 0,2 |
Koersdoel Analisten
Hold
€ 14,45
+116.3%
Forward K/W
2,5
Forward WPA
€ 2,59
WPA Groei (sch.)
+0,0%
Omzet Sch.
29 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 3,62
€ 3,53 – € 3,69
|
39 B | 1 |
| FY2029 |
€ 3,41
€ 3,33 – € 3,48
|
36 B | 1 |
| FY2028 |
€ 3,06
€ 2,98 – € 3,12
|
34 B | 1 |
Belangrijkste Punten
Revenue grew 7,82% annually over 5 years — modest growth
Earnings declined -32,21% over the past year
ROE of 20,09% indicates high profitability
Generating 5,03B in free cash flow
P/E of 4,39 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 10,69%
Groei
Revenue Growth (5Y)
7,82%
Revenue (1Y)-2,87%
Earnings (1Y)-32,21%
FCF Growth (3Y)29,80%
Kwaliteit
Return on Equity
20,09%
ROIC13,79%
Net Margin13,05%
Op. Margin27,19%
Veiligheid
Debt / Equity
1,40
Current Ratio1,61
Interest Coverage9,19
Waardering
P/E Ratio
4,39
P/B Ratio0,93
EV/EBITDA5,15
Dividend Yield0,04%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -2,87% | Revenue Growth (3Y) | 3,52% |
| Earnings Growth (1Y) | -32,21% | Earnings Growth (3Y) | -15,38% |
| Revenue Growth (5Y) | 7,82% | Earnings Growth (5Y) | -8,21% |
| Profitability | |||
| Revenue (TTM) | 26,25B | Net Income (TTM) | 3,43B |
| ROE | 20,09% | ROA | 7,07% |
| Gross Margin | 65,06% | Operating Margin | 27,19% |
| Net Margin | 13,05% | Free Cash Flow (TTM) | 5,03B |
| ROIC | 13,79% | FCF Growth (3Y) | 29,80% |
| Safety | |||
| Debt / Equity | 1,40 | Current Ratio | 1,61 |
| Interest Coverage | 9,19 | Dividend Yield | 0,04% |
| Valuation | |||
| P/E Ratio | 4,39 | P/B Ratio | 0,93 |
| P/S Ratio | 0,57 | PEG Ratio | -1,10 |
| EV/EBITDA | 5,15 | Dividend Yield | 0,04% |
| Market Cap | 15,04B | Enterprise Value | 36,78B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 26,25B | 27,03B | 24,50B | 22,58B | 19,43B |
| Net Income | 3,43B | 5,05B | 4,78B | 4,71B | 4,83B |
| EPS (Diluted) | 1,52 | 2,25 | 2,22 | 2,21 | 2,26 |
| Gross Profit | 17,08B | 18,27B | 16,33B | 15,53B | 13,31B |
| Operating Income | 7,14B | 7,32B | 6,77B | 6,44B | 6,36B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 48,46B | 48,07B | 48,16B | 34,96B | 15,84B |
| Total Liabilities | 32,31B | 30,13B | 30,86B | 26,66B | 7,67B |
| Shareholders' Equity | 16,15B | 17,94B | 17,30B | 8,29B | 8,17B |
| Total Debt | 22,68B | 22,63B | 19,57B | 18,71B | 2,79B |
| Cash & Equivalents | 948,88M | 788,00M | 911,00M | 414,00M | 448,00M |
| Current Assets | 10,47B | 10,44B | 9,94B | 8,77B | 6,99B |
| Current Liabilities | 6,52B | 10,20B | 16,31B | 7,34B | 6,31B |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#211 of 670
Recente Activiteit
Ingestapt
Contrarian Investing (David Dreman)
Mar 24, 2026